Neumora Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
NMRA$0.49-3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Audited Consolidated Financial Statements | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 98 |
| Consolidated Balance Sheets | 102 |
| Consolidated Statements of Operations and Comprehensive Loss | 103 |
| Consolidated Statements of Convertible Preferred Stock Stockholders' Equity (Deficit) | 104 |
| Consolidated Statements of Cash Flows | 105 |
| Notes to the Consolidated Financial Statements | 106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.